The Death of Mid-Budget Horror

For roughly a decade, between 2013 and 2023, American horror cinema had a working economic engine that produced, reliably, a specific kind of film: mid-budget (around $5 to $25 million), director-driven, theatrically-released, and with enough commercial discipline to return a profit. Blumhouse produced this kind of film under Jason Blum’s specific low-budget-high-margin model. A24 and Neon produced adjacent versions. Legacy studios occasionally delivered one. The category included The Witch, Get Out, Hereditary, Midsommar, It Follows, The Babadook, A Quiet Place, Us, The Invitation, The Lighthouse, Saint Maud, X, Pearl, Barbarian.

That category no longer commercially functions in the way it did. I want to argue for why, what was lost, and what is replacing it.

What the economy was

The mid-budget horror film, in its functional decade, operated on specific economics. A $10 million film that opened to $25 million and grossed $80 million worldwide was, after distribution cuts and marketing, profitable. The margin was not enormous, but it was predictable. A studio that produced five of these in a year could count on two or three being hits and one being a sleeper success. The format rewarded discipline: tight running times, specific marketing hooks, a single unified creative vision.

The directors who emerged from this economy, Robert Eggers, Ari Aster, Jordan Peele, Julia Ducournau, David Robert Mitchell, Jennifer Kent, Coralie Fargeat, Jane Schoenbrun, were able to make debut or second features at specific budgets that let them develop their voices without being crushed by the commercial pressure of tentpole production. Most of them have subsequently graduated to larger-budget work. The mid-budget horror film was the farm system that fed American auteur cinema.

What broke

Several things broke roughly simultaneously.

Opening-weekend economics shifted. Across 2022 and 2023, audience behaviour for non-franchise films changed substantially. Films that would have reliably opened to $20-25 million in 2019 were, by 2023, opening at $8-12 million. Marketing that used to work (specifically, cryptic trailer campaigns, viral social-media moments) no longer reliably generated that opening figure. Longlegs in 2024 was the exception that confirmed the pattern: it opened to $22 million because of a specifically disciplined marketing campaign, and then collapsed within two weeks as audience reaction soured. The cryptic-marketing trick, which had sustained mid-budget horror for a decade, had become less reliable.

Streaming atomisation ate the theatrical afterlife. The 2010s mid-budget horror film could count on a robust theatrical run (six to twelve weeks) followed by a lucrative home-entertainment window. By 2024, the theatrical-to-streaming window had collapsed to roughly thirty days, and the home-entertainment economy had been absorbed into flat-rate streaming subscriptions. The back-end revenue that made the mid-budget horror economy work had, structurally, dried up.

Production costs rose. The same $10 million budget that reliably produced a decent mid-budget horror film in 2015 does not produce the same film in 2024. Inflation, union-negotiated post-strike pay scales, and specific cost increases in post-production and VFX have pushed the minimum viable budget for a theatrical-quality horror film up substantially.

The director pipeline got starved upstream. With fewer mid-budget horror films being greenlit, the specific early-career development pathway that had delivered Eggers, Aster, Peele, and Schoenbrun is no longer functioning at the same rate. Young directors are not getting the same opportunities to make second and third features.

What the current market looks like

The horror films being produced in 2024 and 2025 are, increasingly, either much smaller (micro-budget indie horror at under $3 million, usually distributed to streaming or limited theatrical release) or much larger (studio tentpoles at $60 million-plus that are structured as franchise launches). The mid-budget middle has been hollowed out.

Blumhouse, which had been the specific institutional anchor of the mid-budget horror economy, has pivoted. The company’s 2024 releases (Night Swim, Imaginary, Speak No Evil, The Crow under partial distribution) have included several fewer directors-with-voices and more franchise-adjacent product. This is a defensive move. The economic logic no longer supports the earlier approach.

A24 and Neon continue to produce smaller specific-vision horror films, but at lower volume and with specifically narrower theatrical windows. The films they are releasing are good (Perkins’ Longlegs and The Monkey, Mollner’s Strange Darling, various international releases) but the volume is not replacing what Blumhouse used to produce.

What this costs the broader cinema

The loss of the mid-budget horror economy is not, primarily, a loss for horror. The films that the economy produced still exist; most of them will continue to be watched and studied. The loss is for the larger American film ecosystem, which used this economy as its main directorial development pipeline.

Consider: where did Ari Aster come from? Two short films, then Hereditary (budget around $10 million), then Midsommar (around $9 million). He is now making $60-80 million films (Beau Is Afraid, Eddington) with A24. The path from short films to prestige-budget auteur cinema ran through the mid-budget horror market. Without the mid-budget horror market, that path does not exist.

The next generation of American auteur cinema, the directors who should be emerging in 2025 and 2026 with their breakout second features, is arriving in a smaller quantity and with less discipline because the specific institutional apparatus that trained and supported the previous generation has been substantially dismantled.

What might be replacing it

A few tentative replacements have been attempting to emerge. International co-productions (particularly between American and Korean, French, and British horror specialists) have produced some of the year’s most interesting films. Streaming-funded horror at premium-adjacent budgets (Netflix’s and Amazon’s occasional prestige-horror plays) has delivered specifically uneven results. Micro-budget indie horror with viral-marketing-led theatrical crossover (the Rose Glass and Emma Tammi wave) has shown some promise.

None of these replacements are, yet, operating at the scale the mid-budget horror economy did in its decade.

What I am watching for

Two questions will be answered by 2027 or so.

First: whether the collapsed theatrical window will reverse. If streaming economics continue to starve theatrical-afterlife revenue, the mid-budget horror economy will not return. If specific distributors (A24, Neon, maybe Focus) can reconstruct a longer theatrical window, some of the economics could come back.

Second: whether the next generation of American auteur cinema gets made at all. We will know by roughly 2027 whether the current pipeline contraction has produced a gap in the auteur-development path. If it has, American cinema of the late 2020s and 2030s will be measurably thinner than it would otherwise have been.

I am not optimistic on either question. But the industrial situation is not yet fully locked in, and there are specific things specific distributors could do to restore some of what has been lost. I would like to see them try.